Cadrenal Therapeutics, Inc. (CVKD)
Nasdaq: CVKD · Pharmaceutical Preparations · Ponte Vedra, FL · filing with the SEC since 2022
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2008 |
|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Mar 31, 2008 |
| Report filed | Mar 31, 2026 | Mar 13, 2025 | Mar 11, 2024 | Mar 30, 2023 | · |
| Cost of revenue | · | · | 220,095 | · | 220,095 |
| Research and development | 4,100,168 | 4,205,013 | 4,081,349 | · | 200,000 |
| General and administrative | 9,354,135 | 6,753,726 | 3,549,514 | · | · |
| Total operating expenses | 13,461,177 | 10,960,619 | 7,632,843 | · | · |
| Operating income | -13,461,177 | -10,960,619 | -7,632,843 | · | · |
| Interest expense | · | · | 3,534 | · | · |
| Interest and investment income | 223,815 | 309,251 | 249,092 | · | · |
| Total non-operating income (expense) | 223,815 | 309,251 | -724,243 | · | · |
| Net income | -13,237,362 | -10,651,368 | -8,357,086 | · | · |
| Net income to common shareholders | -13,237,362 | -10,651,368 | -8,357,086 | · | · |
| Earnings per share, basic | -6.64 | -8.73 | -9.29r | · | · |
| Earnings per share, diluted | -6.64 | -8.73 | -9.29r | · | · |
| Weighted average shares, basic | 1,993,757 | 1,219,550 | 899,465r | · | · |
| Weighted average shares, diluted | 1,993,757 | 1,219,550 | 899,465r | · | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-15 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Cost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpense
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestAndDividendTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding